ES2165366T3 - Procedimientos y composiciones para inhibir la inflamacion mediada por celulas endoteliales y fibrinogeno. - Google Patents

Procedimientos y composiciones para inhibir la inflamacion mediada por celulas endoteliales y fibrinogeno.

Info

Publication number
ES2165366T3
ES2165366T3 ES93916500T ES93916500T ES2165366T3 ES 2165366 T3 ES2165366 T3 ES 2165366T3 ES 93916500 T ES93916500 T ES 93916500T ES 93916500 T ES93916500 T ES 93916500T ES 2165366 T3 ES2165366 T3 ES 2165366T3
Authority
ES
Spain
Prior art keywords
fibrinogen
binding
inhibit
procedures
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93916500T
Other languages
English (en)
Inventor
Lucia R Languino
Dario C Altieri
Edward F Plow
John E Geltosky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Application granted granted Critical
Publication of ES2165366T3 publication Critical patent/ES2165366T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION CONTEMPLA LAS COMPOSICIONES TERAPEUTICAS QUE CONTIENEN UN HOMOLOGO DE FIBRINOGENO CAPAZ DE UNIRSE A LAS CELULAS ENDOTELIALES EN UN FORMA INDEPENDIENTE DE RGD QUE INHIBE LA UNION DE FIBRINOGENO A LAS CELULAS ENDOTELIALES. TAMBIEN SON DESCRITOS LAS COMPOSICIONES TERAPEUTICAS QUE CONTIENEN UN HOMOLOGO ICAM-1 CAPAZ DE UNIRSE AL FIBRINOGENO EN UNA FORMA INDEPENDIENTE DE RGD QUE INHIBE AL FIBRINOGENO UNIRSE A LAS CELULAS ENDOTELIALES. SON TAMBIEN CONTEMPLADOS LOS METODOS DE INHIBIR LA INFLAMACION TRANSMITIDA DE FIBRINOGENO Y CELULA ENDOTELIAL.
ES93916500T 1992-06-11 1993-06-11 Procedimientos y composiciones para inhibir la inflamacion mediada por celulas endoteliales y fibrinogeno. Expired - Lifetime ES2165366T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89811792A 1992-06-11 1992-06-11

Publications (1)

Publication Number Publication Date
ES2165366T3 true ES2165366T3 (es) 2002-03-16

Family

ID=25408971

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93916500T Expired - Lifetime ES2165366T3 (es) 1992-06-11 1993-06-11 Procedimientos y composiciones para inhibir la inflamacion mediada por celulas endoteliales y fibrinogeno.

Country Status (9)

Country Link
EP (1) EP0644768B1 (es)
AT (1) ATE209040T1 (es)
AU (1) AU675073B2 (es)
CA (1) CA2137813A1 (es)
DE (1) DE69331193T2 (es)
DK (1) DK0644768T3 (es)
ES (1) ES2165366T3 (es)
PT (1) PT644768E (es)
WO (1) WO1993025218A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4880153B2 (ja) * 1999-06-24 2012-02-22 ザ ジョンズ ホプキンス ユニヴァーシティ Ｈｉｖの経上皮伝染を予防する組成物および方法
US9901625B2 (en) 2011-10-15 2018-02-27 University Of Maryland, College Park Methods of regulating uptake and transcellular transport of leukocytes and therapeutics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3203775A1 (de) * 1982-02-04 1983-08-11 Behringwerke Ag, 3550 Marburg Fibrinogenzubereitung, verfahen zu ihrer herstellungund ihre verwendung
WO1990003400A1 (en) * 1988-09-28 1990-04-05 Dana-Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US5473051A (en) * 1990-07-19 1995-12-05 The Scripps Research Institute Inhibition of Mac-1 receptor binding to fibrinogen using D30 homologs

Also Published As

Publication number Publication date
EP0644768A1 (en) 1995-03-29
CA2137813A1 (en) 1993-12-23
ATE209040T1 (de) 2001-12-15
AU675073B2 (en) 1997-01-23
PT644768E (pt) 2002-03-28
WO1993025218A1 (en) 1993-12-23
DE69331193D1 (de) 2002-01-03
DE69331193T2 (de) 2002-04-18
AU4632793A (en) 1994-01-04
EP0644768A4 (en) 1997-06-11
DK0644768T3 (da) 2002-05-21
EP0644768B1 (en) 2001-11-21

Similar Documents

Publication Publication Date Title
MX163955B (es) Composicion farmaceutica de dihidrocodeina e ibuprofen
DE69727158D1 (de) Pharmazeutische zusammensetzungen enthaltend eine mischung von selbstvernetzter und nichtselbstvernetzter hyaluronsäure zur behandlung von arthropathien
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
ATE242633T1 (de) Dialkylfumarate zur behandlung von autoimmunerkrankungen
TW283645B (es)
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
ES8505405A1 (es) Un procedimiento para producir un activador de plasminogeno purificado.
ZA947338B (en) Use of angiotensin II and analogs thereof in tissue repair
ES2069750T3 (es) Metodos y composiciones para curar huesos.
ES2057124T3 (es) Producto terapeutico para el tratamiento de estados peri- o post-menopausicos.
FI953748A0 (fi) Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina
HUP0100539A2 (hu) D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására
DK0443224T3 (da) Anvendelse af thrombospondin til fremskyndelse af sårheling
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
MX9203374A (es) Composicion farmaceutica que contiene l-alfa-glicerofosforilcolina.
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
DE3582594D1 (de) Proglumid und dessen pharmazeutische zusammensetzungen zur anwendung bei der behandlung von neoplastischen affektionen.
DK0484112T3 (da) Anvendelse af lithium ved behandlingen eller profylakse af Molluscum contagiosum
IT8821634A0 (it) Composizioni farmaceutiche che favoriscono la cicatrizzazione di ferite e procedimento per prepararle
ES2165366T3 (es) Procedimientos y composiciones para inhibir la inflamacion mediada por celulas endoteliales y fibrinogeno.
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
ATE222768T1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
DK139685A (da) Liposomer med inhalative allergener til behandling af allergier, fremgangsmaade til deres fremstilling og laegemidler indeholdende disseliposomer
BR9913846A (pt) Antagonista receptor de quemocina e ciclosporina em terapia combinada

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 644768

Country of ref document: ES